What is Zacks Research's Forecast for PAHC Q2 Earnings?

Phibro Animal Health Co. (NASDAQ:PAHC - Free Report) - Investment analysts at Zacks Research dropped their Q2 2025 earnings per share estimates for Phibro Animal Health in a report released on Wednesday, November 20th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.35 per share for the quarter, down from their previous forecast of $0.40. The consensus estimate for Phibro Animal Health's current full-year earnings is $1.59 per share. Zacks Research also issued estimates for Phibro Animal Health's Q4 2025 earnings at $0.41 EPS, FY2025 earnings at $1.46 EPS, Q2 2026 earnings at $0.46 EPS, Q4 2026 earnings at $0.48 EPS, FY2026 earnings at $1.59 EPS and FY2027 earnings at $2.10 EPS.

Several other research analysts have also issued reports on the stock. StockNews.com lowered shares of Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Wednesday. JPMorgan Chase & Co. started coverage on shares of Phibro Animal Health in a research report on Tuesday, September 10th. They set a "neutral" rating and a $22.00 price objective on the stock. Bank of America lifted their price objective on shares of Phibro Animal Health from $13.00 to $15.00 and gave the stock an "underperform" rating in a research report on Friday, August 30th. Finally, Barclays lifted their price objective on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an "underweight" rating in a research report on Tuesday, November 12th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $16.50.

Phibro Animal Health Price Performance

Phibro Animal Health stock traded down $0.02 during mid-day trading on Friday, hitting $23.74. The company's stock had a trading volume of 132,855 shares, compared to its average volume of 158,760. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81. The stock has a market capitalization of $961.54 million, a P/E ratio of 55.26, a P/E/G ratio of 0.62 and a beta of 0.51. Phibro Animal Health has a twelve month low of $9.49 and a twelve month high of $25.98. The stock's fifty day moving average price is $23.13 and its two-hundred day moving average price is $19.94.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.07. The firm had revenue of $273.16 million for the quarter, compared to analyst estimates of $262.44 million. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Stockholders of record on Wednesday, November 27th will be issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 2.02%. The ex-dividend date is Wednesday, November 27th. Phibro Animal Health's dividend payout ratio is currently 111.63%.

Insider Activity

In other Phibro Animal Health news, Director E Thomas Corcoran acquired 5,000 shares of Phibro Animal Health stock in a transaction that occurred on Wednesday, September 4th. The stock was acquired at an average price of $20.02 per share, with a total value of $100,100.00. Following the purchase, the director now owns 25,000 shares in the company, valued at approximately $500,500. This trade represents a 25.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 50.07% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Phibro Animal Health

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its position in Phibro Animal Health by 3.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 24,336 shares of the company's stock worth $548,000 after acquiring an additional 729 shares during the last quarter. CWM LLC lifted its position in Phibro Animal Health by 89.8% during the 2nd quarter. CWM LLC now owns 2,188 shares of the company's stock worth $37,000 after acquiring an additional 1,035 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Phibro Animal Health by 7.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,393 shares of the company's stock worth $200,000 after acquiring an additional 1,063 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Phibro Animal Health by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company's stock worth $88,000 after acquiring an additional 1,522 shares during the last quarter. Finally, Cardinal Capital Management lifted its position in Phibro Animal Health by 4.7% during the 2nd quarter. Cardinal Capital Management now owns 56,027 shares of the company's stock worth $940,000 after acquiring an additional 2,520 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company's stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.